"These diagnostic imaging agents allow physicians to determine – for the first time – whether living patients have beta-amyloid plaques in their brain," said Mark Mintun, M.D., chief medical officer, Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly. "This information may impact how physicians ultimately treat their patients by helping inform diagnostic decisions. However, patient outcomes are largely due to the physician's ability to make an accurate diagnosis and recommend an appropriate treatment plan."About Alzheimer's Disease By 2030, the total number of Americans aged 65 and over with Alzheimer's Disease is expected to reach 7.7 million. 3 In response to this mounting national health threat, the National Alzheimer's Project Act has brought about renewed urgency and focus on developing new and innovative ways to diagnose, support and treat patients suffering from Alzheimer's Disease. 4
Lilly Supports The Medical Community's Testimony On The Clinical Utility Of Beta-Amyloid Imaging Agents, Such As Amyvid™ (Florbetapir F 18 Injection), During CMS Public Hearing
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.